UCL Technology Fund

Oriole Networks is a company focused on improving the performance of artificial intelligence systems and enhancing the efficiency of data centers. By leveraging advanced optimization techniques and resource utilization strategies, Oriole Networks aims to accelerate machine learning processes while significantly reducing energy consumption. This commitment to innovation not only enhances AI performance but also promotes sustainable practices across various industries, contributing to a more environmentally friendly future.

Gaussion is a company focused on enhancing electric vehicle charging through an innovative approach that leverages magneto-electrochemistry. Their technology enables rapid charging by directing ions within existing battery cells using magnetic fields. This method not only facilitates faster charging but also reduces cell degradation, thereby extending the overall lifespan of the batteries. By implementing this novel solution, Gaussion aims to improve the efficiency of electric vehicle usage without necessitating modifications to the vehicles or their batteries.

Oriole Networks is a company focused on improving the performance of artificial intelligence systems and enhancing the efficiency of data centers. By leveraging advanced optimization techniques and resource utilization strategies, Oriole Networks aims to accelerate machine learning processes while significantly reducing energy consumption. This commitment to innovation not only enhances AI performance but also promotes sustainable practices across various industries, contributing to a more environmentally friendly future.

Stanhope is a real estate firm based in London, England, specializing in the development of significant commercial and mixed-use properties. The company focuses on creating and delivering projects primarily in London and the South East, encompassing a range of real estate sectors, including office and retail spaces. With a commitment to quality and innovation, Stanhope plays a key role in shaping urban environments through its diverse portfolio of developments.

Stanhope AI teaches robots and machines how to make decisions in the real world, with a particular focus on allowing them to tackle situations in which they have received no training.

Echopoint Medical Ltd is a medical device company specializing in the development of optical-fibre based sensors aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Originating as a spin-out from University College London, the company focuses on integrating innovative sensing modalities into minimally invasive medical procedures. These advanced devices offer unprecedented imaging and sensing capabilities, which help healthcare providers improve patient outcomes while reducing costs and complications associated with cardiac surgeries. By leveraging breakthroughs in fibre optic sensor technology, Echopoint Medical addresses critical unmet needs for patients and clinicians alike.

Phasecraft is a UK-based company founded in 2018 that develops quantum software aimed at enhancing the practical application of quantum computing. The firm focuses on creating algorithms for quantum information processors, including intermediate-scale devices and quantum computers. By leveraging its expertise in quantum science and engineering, Phasecraft addresses significant industrial challenges, such as optimizing key processes and exploring new materials. The company's software supports clients in investigating innovative quantum materials and developing advanced technologies, including batteries and efficient solar cells. Through its work, Phasecraft aims to facilitate breakthrough scientific discoveries and enable entrepreneurs to tackle pressing global issues more effectively.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Gaussion is a company focused on enhancing electric vehicle charging through an innovative approach that leverages magneto-electrochemistry. Their technology enables rapid charging by directing ions within existing battery cells using magnetic fields. This method not only facilitates faster charging but also reduces cell degradation, thereby extending the overall lifespan of the batteries. By implementing this novel solution, Gaussion aims to improve the efficiency of electric vehicle usage without necessitating modifications to the vehicles or their batteries.

Hazy Limited is a London-based company that specializes in data anonymization through artificial intelligence. Founded in 2017, Hazy develops a workflow tool that enables businesses to securely share and utilize data while complying with privacy regulations. The platform automatically anonymizes personal information, allowing organizations to handle evolving datasets without compromising sensitive data. By re-engineering enterprise data, Hazy empowers businesses to enhance decision-making, foster innovation, and create value, all while ensuring that data remains reliable, safe, and trusted. Hazy positions itself as a leader in the synthetic data space, addressing the growing demand for accessible and usable data in an increasingly regulated environment.

Intrinsic Semiconductor Technologies focuses on developing silicon-oxide-based resistive random-access memory (RRAM) technologies. The company specializes in creating memristive devices that serve as next-generation non-volatile memory solutions. Their technology is fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes, allowing for integration into standard devices even at advanced process nodes. This capability enables the production of low-power, cost-effective semiconductors that can operate under higher power ratings, including elevated frequencies and temperatures. Intrinsic's offerings can be configured for various applications, such as multilevel memory, hardware acceleration for machine learning, and neuromorphic computing, positioning the company at the forefront of innovation in the semiconductor industry.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.

Bloomsbury Genetic Therapies is a clinical-stage biotechnology company focused on developing curative treatments for rare neurological and metabolic diseases through gene therapy technologies. The company aims to provide effective and safe therapies for devastating pediatric neurodegenerative conditions, such as infantile neuroaxonal dystrophy, for which there are currently no available treatments. By leveraging clinically proven gene therapy approaches, Bloomsbury seeks to create a pipeline of first- or best-in-class programs that offer the potential for high manufacturability and accelerated development. Their mission is to address significant unmet medical needs in this challenging therapeutic area.

Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board (PCB) fuel cells, specifically proton exchange membrane fuel cells (PEMFCs). Incorporated in 2015, it leverages the capabilities of the global PCB industry to produce high-performance, cost-effective fuel cell stacks. The company's product lineup includes modular PCBFC stacks, ranging from 20 W to 5 kW, as well as custom-designed solutions. Bramble Energy serves various sectors, including stationary, portable, and automotive applications, aiming to provide gigawatts of fuel cell hardware. By utilizing innovative manufacturing methods and materials, the company enables clients to reduce energy consumption and lower their carbon footprints.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.

Apollo Therapeutics is a biopharmaceutical company based in Cambridge, United Kingdom, that collaborates with three leading UK universities—Imperial College London, University College London, and the University of Cambridge—and three major pharmaceutical companies. The company focuses on translating groundbreaking medical research into effective therapeutics, facilitating the development of pre-clinical and clinical-stage assets. Apollo Therapeutics manages a venture capital fund that provides financial and technical support for innovative projects sourced from top British academic research, with a particular emphasis on areas such as oncology, major inflammatory disorders, and rare diseases. By leveraging its experienced team of industry scientists, Apollo aims to optimize therapeutic delivery and enhance patient treatments and outcomes, establishing a strong link between academia and the pharmaceutical industry to foster impactful medical advancements.

Intrinsic Semiconductor Technologies focuses on developing silicon-oxide-based resistive random-access memory (RRAM) technologies. The company specializes in creating memristive devices that serve as next-generation non-volatile memory solutions. Their technology is fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes, allowing for integration into standard devices even at advanced process nodes. This capability enables the production of low-power, cost-effective semiconductors that can operate under higher power ratings, including elevated frequencies and temperatures. Intrinsic's offerings can be configured for various applications, such as multilevel memory, hardware acceleration for machine learning, and neuromorphic computing, positioning the company at the forefront of innovation in the semiconductor industry.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board (PCB) fuel cells, specifically proton exchange membrane fuel cells (PEMFCs). Incorporated in 2015, it leverages the capabilities of the global PCB industry to produce high-performance, cost-effective fuel cell stacks. The company's product lineup includes modular PCBFC stacks, ranging from 20 W to 5 kW, as well as custom-designed solutions. Bramble Energy serves various sectors, including stationary, portable, and automotive applications, aiming to provide gigawatts of fuel cell hardware. By utilizing innovative manufacturing methods and materials, the company enables clients to reduce energy consumption and lower their carbon footprints.

Humanloop Ltd is a London-based company that specializes in developing an artificial intelligence data labeling and model training platform aimed at enhancing the efficiency of businesses in deploying machine learning solutions. Established in 2020, Humanloop's tools facilitate the training of AI models using minimal labeled data, allowing engineers and data scientists to expedite the transition from concept to deployment. The platform supports best practices in prompt management, evaluation, and observability, enabling organizations to effectively leverage AI technologies. Notable clients, including teams from Gusto, Vanta, and Duolingo, utilize Humanloop's offerings to create reliable AI products and improve their operational capabilities.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Astroscreen Ltd is a London-based company that specializes in developing a software as a service (SaaS) platform aimed at detecting astroturfing campaigns, which involve deceptive social media manipulation. Founded in 2018, the platform employs advanced machine learning techniques and human intelligence to identify fake accounts, botnets, and spam across social networks. By leveraging social media bot data, Astroscreen provides disinformation analysts with the tools needed to verify social media influence engagement and cleanse data streams. This enables organizations to combat marketing fraud, safeguard their brands, and obtain reliable insights into social media analytics.

Phasecraft is a UK-based company founded in 2018 that develops quantum software aimed at enhancing the practical application of quantum computing. The firm focuses on creating algorithms for quantum information processors, including intermediate-scale devices and quantum computers. By leveraging its expertise in quantum science and engineering, Phasecraft addresses significant industrial challenges, such as optimizing key processes and exploring new materials. The company's software supports clients in investigating innovative quantum materials and developing advanced technologies, including batteries and efficient solar cells. Through its work, Phasecraft aims to facilitate breakthrough scientific discoveries and enable entrepreneurs to tackle pressing global issues more effectively.

Scout is developing an innovative web assistance technology that aims to transform how individuals navigate the internet. The company is creating a content-aware browser that not only presents webpages but also comprehends their content and understands user intentions across multiple tasks. This advanced browser will function as a digital assistant, facilitating various online activities such as shopping by finding alternative prices and summarizing reviews, and event planning by checking users' calendars and suggesting routes. By employing techniques such as semantic graphing, natural language processing, and reinforcement learning, Scout's software will enable users to access relevant information seamlessly, eliminating the need for manual searches and enhancing overall online efficiency.

KIT-AR Ltd is a company based in London, United Kingdom, that specializes in designing and developing integrated industrial augmented reality systems aimed at enhancing manufacturing productivity across various industries, including automotive, aerospace, and electronics. Founded in 2018, KIT-AR focuses on providing solutions that help reduce production errors and improve quality assurance on the shop floor. The company's offerings include KIT-ASSIST, which delivers specialist knowledge through a heads-up display; KIT-SMART, a set of intelligent modules that monitor the working environment and worker activity; KIT-BUILD, which manages work instructions; and KIT-INSIGHT, which provides insights into productivity and efficiency. By connecting and empowering shop floor employees with timely information and automated quality checks, KIT-AR enables manufacturers to minimize unplanned downtime and achieve higher accuracy in their operations.

Hazy Limited is a London-based company that specializes in data anonymization through artificial intelligence. Founded in 2017, Hazy develops a workflow tool that enables businesses to securely share and utilize data while complying with privacy regulations. The platform automatically anonymizes personal information, allowing organizations to handle evolving datasets without compromising sensitive data. By re-engineering enterprise data, Hazy empowers businesses to enhance decision-making, foster innovation, and create value, all while ensuring that data remains reliable, safe, and trusted. Hazy positions itself as a leader in the synthetic data space, addressing the growing demand for accessible and usable data in an increasingly regulated environment.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing innovative adeno-associated virus (AAV) vector-mediated gene therapies aimed at treating inherited systemic diseases. The company employs engineered AAV vectors and capsids, alongside novel promoters and transgenes, to introduce functional copies of therapeutic genes into human liver cells. This process allows for the production of essential proteins in the bloodstream, addressing deficiencies caused by genetic disorders. Freeline's key product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1. Their ongoing development programs encompass various clinical trials to advance these gene therapies and provide transformative solutions for patients suffering from debilitating conditions.

Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Hazy Limited is a London-based company that specializes in data anonymization through artificial intelligence. Founded in 2017, Hazy develops a workflow tool that enables businesses to securely share and utilize data while complying with privacy regulations. The platform automatically anonymizes personal information, allowing organizations to handle evolving datasets without compromising sensitive data. By re-engineering enterprise data, Hazy empowers businesses to enhance decision-making, foster innovation, and create value, all while ensuring that data remains reliable, safe, and trusted. Hazy positions itself as a leader in the synthetic data space, addressing the growing demand for accessible and usable data in an increasingly regulated environment.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Bloomsbury AI Limited was a London-based company that specialized in developing a Software as a Service (SaaS) platform for creating text-understanding computer applications. Founded in April 2015 by a team that included Guillaume Bouchard and Sebastian Riedel, the company's technology utilized artificial intelligence to read documents and learn from user interactions, allowing it to perform tasks similarly to how human apprentices acquire skills. This platform aimed to automate expertise through written dialogue, enabling users to efficiently execute repetitive tasks and streamline their workflows. Although Bloomsbury AI was once a subsidiary of Facebook, it ultimately went into liquidation.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing innovative adeno-associated virus (AAV) vector-mediated gene therapies aimed at treating inherited systemic diseases. The company employs engineered AAV vectors and capsids, alongside novel promoters and transgenes, to introduce functional copies of therapeutic genes into human liver cells. This process allows for the production of essential proteins in the bloodstream, addressing deficiencies caused by genetic disorders. Freeline's key product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1. Their ongoing development programs encompass various clinical trials to advance these gene therapies and provide transformative solutions for patients suffering from debilitating conditions.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.